Moose Whose Lingering Closed Mountain Trail for 2 Months Is Euthanized
The decision to humanely end the moose's life came after wildlife biologists with the Department of Environmental Conservation and the state wildlife veterinarian visited the area near the Goodman Mountain summit where the moose had been a fixture since May.
During the visit, the environmental conservation team observed 'advanced signs of disease, including severe emaciation,' the department said in a news release on Thursday.
Jacqueline Lendrum, the director of the agency's fish and wildlife division, said in a statement that the moose's 'deteriorating condition' had given it 'a low likelihood of survival.'
The agency's priority 'is always the well-being of wildlife and public safety,' she said. 'Humane euthanasia is sometimes the most responsible course of action.'
The moose was first spotted in May near the summit of Goodman Mountain, in Horseshoe Lake Wild Forest west of Lake Placid, by hikers who reported that it was letting them come close.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
‘Kitten Lady' Hannah Shaw Teams with Hill's Pet Nutrition to Discuss Clear The Shelters 2025 with YourUpdateTV
NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Shelters across the country continue to face capacity challenges, slowed adoptions and stretched resources, with 5.8 million cats and dogs entering shelters last year alone, according to Shelter Animals Count. Now in its 11th year, NBCUniversal Local's Clear The Shelters campaign returns alongside Hill's Pet Nutrition (Hill's), the campaign's longest-running national sponsor, to help address the crisis and encourage shelter adoptions. Recently, Award-Winning Kitten Rescuer and Best-Selling Author, Kitten Lady Hannah Shaw, teamed with Hill's for a nationwide media tour to share helpful tips for prospective pet parents, from preparing your home to getting a healthy start with high-quality nutrition. She talked about what adopters can expect during the adjustment period, including how to build trust, encourage healthy routines and integrate a new pet into the family. Shaw also spoke to the unspoken feeling that in order to adopt, one has to be the 'perfect pet parent.' According to Hill's 2025 State of Shelter Pet Adoption Report, younger Americans often feel a pressure to meet a 'gold standard' of pet care, leading to hesitation and guilt about adoption. Shaw reassured that committed care, even if imperfect, is truly enough and that much of pet parenthood is learned through experience. Since 2015, Clear The Shelters has helped nearly 1.2 million pets find loving homes and raised more than $5 million for participating shelters across the country. After setting a single-year adoption record in 2024, this year's goal is bigger than ever: make 2025 another record-breaking year and give even more pets a second chance. During Clear The Shelters, Hill's continues its 23-year commitment to shelter pets and animal welfare professionals through its Hill's Food, Shelter & Love program. The program has supported more than 15 million adoptions and donated more than $300 million in science-led nutrition to more than 1,000 North American shelters. There are many ways to get involved with Clear The Shelters: Visit to find more information about Clear The Shelters 2025 and resources about Hill's Pet Nutrition and its support of shelter pets. About Hannah Shaw Hannah Shaw is an award-winning kitten rescuer, humane educator and New York Times bestselling author dedicated to protecting vulnerable felines. Known as Kitten Lady, she creates educational content used by shelters and foster parents worldwide, with over 4 million followers across social platforms. Shaw is the founder of the nonprofit Orphan Kitten Club and author of Tiny But Mighty and Cats of the World. She lives in California with her husband, fellow animal advocate Andrew Marttila, and a rotating cast of foster kittens. * YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of Hill's Pet Nutrition Dante Muccigrosso Director of Media Integration & Client Reporting E: [email protected] C: 973.524.0104 A video accompanying this release is available at
Axios
6 hours ago
- Axios
Eight Sleep raises $100 million, preps retail stores
Eight Sleep, a New York-based developer of smart sleep products, has raised $100m in Series D funding. Why it matters: This comes just weeks after RFK Jr. said that the Department of Health and Human Services will launch a giant advertising campaign aimed at encouraging the use of wearables. "My vision is that every American is wearing a wearable within four years," he told Congress. Eight Sleep's smart mattress cover isn't technically a wearable — users lie on top of it — but still fits within the category. Investors include HSG (fka: HongShan Capital/Sequoia Capital China) and insiders Valor Equity Partners, Founders Fund, and Y Combinator. Existing backer Khosla Ventures didn't participate.
Yahoo
8 hours ago
- Yahoo
Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift
Medtronic plc (NYSE:MDT) announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately. This move comes shortly after Elliott Investment Management became the company's largest shareholder. The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business. The medtech giant is scheduled to host an Investor Day in mid-2026, as first reported by The Wall Street reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%. Adjusted earnings of $1.26 per share also beat expectations of $1.23. 'We're confident and well-positioned to accelerate our revenue growth in the second half of our fiscal year, as we make meaningful progress on our major growth drivers,' said Geoff Martha, Medtronic chairman and CEO. Cardiovascular Portfolio revenue of $3.285 billion increased 9.3% as reported and 7.0% organic, with a high-single digit increase in Cardiac Rhythm & Heart Failure, mid-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis. Neuroscience Portfolio revenue of $2.416 billion increased 4.3% reported and 3.1% organic, with a high-single digit increase in Neuromodulation and mid-single digit increase in Cranial & Spinal Technologies, offset by a low-single digit decrease in Specialty Therapies. View more earnings on MDT Medical Surgical Portfolio revenue of $2.083 billion grew 4.4% as reported and 2.4% organic, with low-single digit organic growth in both Surgical & Endoscopy and Acute Care & Monitoring. Diabetes business revenue of $721 million increased 11.5% as reported and 7.9% organic. Outlook Medtronic reiterates its fiscal year 2026 organic revenue growth guidance of 5%. The company revised its fiscal 2026 revenue growth on a reported basis from 4.8%-5.1% to 6.5%-6.8%. It raised sales guidance from $35.15 billion-$35.25 billion to $35.72 billion-$35.82 billion versus the consensus of $35.32 billion. Excluding the potential impact from tariffs, Medtronic expects underlying fiscal 2026 adjusted EPS growth to be approximately 4.5% versus the prior guidance of approximately 4%. Including the reduced potential impact from tariffs of approximately $185 million versus the prior range of roughly $200 million to $350 million, Medtronic raised its fiscal 2026 adjusted earnings to $5.60-$5.66 from the prior range of $5.50-$5.60 versus the consensus of $5.55. In July, a federal appeals court sided with Medtronic in a long-running patent dispute, reversing a jury's finding that the company induced infringement of a Colibri Heart Valve LLC patent related to the implantation of artificial heart valves. Price Action: MDT stock is trading lower by 2.00% to $90.95 premarket at last check Tuesday. Read Next:Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MEDTRONIC (MDT): Free Stock Analysis Report This article Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
